Aortic insufficiency medical management: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 7: Line 7:
{{Editor Join}}
{{Editor Join}}


Medical therapy of chronic aortic insufficiency involves the use of [[vasodilators]].  Small trials have demonstrated a benefit from the administration of [[ACE inhibitor]]s, [[nifedipine]], and [[hydralazine]] in improving left ventricular wall stress, [[ejection fraction]], and left ventricular mass.  The use of these vasodilators is indicated only in those individuals who suffer from [[hypertension]] in addition to aortic insufficiency.  The goal in using these pharmacologic agents is to decrease the [[afterload]] so that the left ventricle is unloaded.
Medical therapy of chronic aortic insufficiency involves the use of [[vasodilators]].  Small trials have demonstrated a benefit from the administration of [[ACE inhibitor]]s, [[nifedipine]], [[sodium nitroprusside]] and [[hydralazine]] in improving left ventricular wall stress, [[ejection fraction]], and left ventricular mass <ref name="pmid1260993">{{cite journal |author=Bolen JL, Alderman EL |title=Hemodynamic consequences of afterload reduction in patients with chronic aortic regurgitation |journal=[[Circulation]] |volume=53 |issue=5 |pages=879–83 |year=1976 |month=May |pmid=1260993 |doi= |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=1260993 |accessdate=2011-03-23}}</ref> <ref name="pmid983953">{{cite journal |author=Miller RR, Vismara LA, DeMaria AN, Salel AF, Mason DT |title=Afterload reduction therapy with nitroprusside in severe aortic regurgitation: improved cardiac performance and reduced regurgitant volume |journal=[[The American Journal of Cardiology]] |volume=38 |issue=5 |pages=564–7 |year=1976 |month=November |pmid=983953 |doi= |url= |accessdate=2011-03-23}}</ref>  <ref name="pmid7379285">{{cite journal |author=Greenberg BH, DeMots H, Murphy E, Rahimtoola S |title=Beneficial effects of hydralazine on rest and exercise hemodynamics in patients with chronic severe aortic insufficiency |journal=[[Circulation]] |volume=62 |issue=1 |pages=49–55 |year=1980 |month=July |pmid=7379285 |doi= |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=7379285 |accessdate=2011-03-23}}</ref> <ref name="pmid7081058">{{cite journal |author=Fioretti P, Benussi B, Scardi S, Klugmann S, Brower RW, Camerini F |title=Afterload reduction with nifedipine in aortic insufficiency |journal=[[The American Journal of Cardiology]] |volume=49 |issue=7 |pages=1728–32 |year=1982 |month=May |pmid=7081058 |doi= |url= |accessdate=2011-03-23}}</ref>.  The use of these vasodilators is indicated only in those individuals who suffer from [[hypertension]] in addition to aortic insufficiency.  The goal in using these pharmacologic agents is to decrease the [[afterload]] so that the left ventricle is unloaded. This results in reduction in left ventricular end diastolic pressure thereby preserving the left ventricular systolic function and also benefits the patients in [[left ventricular failure]] secondary to aortic insufficiency.
 
Long term therapy with [[nifedipine]] and [[hydralazine]] have shown to increase left ventricular ejection fraction, reduce left ventricular end diastolic volume and reduction in left ventricular mass thereby delaying the need for valve surgery <ref name="pmid8058074">{{cite journal |author=Scognamiglio R, Rahimtoola SH, Fasoli G, Nistri S, Dalla Volta S |title=Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function |journal=[[The New England Journal of Medicine]] |volume=331 |issue=11 |pages=689–94 |year=1994 |month=September |pmid=8058074 |doi=10.1056/NEJM199409153311101 |url=http://dx.doi.org/10.1056/NEJM199409153311101 |accessdate=2011-03-23}}</ref> <ref name="pmid3289791">{{cite journal |author=Greenberg B, Massie B, Bristow JD, Cheitlin M, Siemienczuk D, Topic N, Wilson RA, Szlachcic J, Thomas D |title=Long-term vasodilator therapy of chronic aortic insufficiency. A randomized double-blinded, placebo-controlled clinical trial |journal=[[Circulation]] |volume=78 |issue=1 |pages=92–103 |year=1988 |month=July |pmid=3289791 |doi= |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=3289791 |accessdate=2011-03-23}}</ref> <ref name="pmid2197314">{{cite journal |author=Scognamiglio R, Fasoli G, Ponchia A, Dalla-Volta S |title=Long-term nifedipine unloading therapy in asymptomatic patients with chronic severe aortic regurgitation |journal=[[Journal of the American College of Cardiology]] |volume=16 |issue=2 |pages=424–9 |year=1990 |month=August |pmid=2197314 |doi= |url=http://linkinghub.elsevier.com/retrieve/pii/0735-1097(90)90596-H |accessdate=2011-03-23}}</ref>. While [[ACE inhibitor]]s such as enalapril and quinapril have shown to decrease left ventricular mass and end diastolic volume but with no influence on ejection fraction <ref name="pmid7930196">{{cite journal |author=Lin M, Chiang HT, Lin SL, Chang MS, Chiang BN, Kuo HW, Cheitlin MD |title=Vasodilator therapy in chronic asymptomatic aortic regurgitation: enalapril versus hydralazine therapy |journal=[[Journal of the American College of Cardiology]] |volume=24 |issue=4 |pages=1046–53 |year=1994 |month=October |pmid=7930196 |doi= |url=http://linkinghub.elsevier.com/retrieve/pii/0735-1097(94)90868-0 |accessdate=2011-03-23}}</ref> <ref name="pmid8000584">{{cite journal |author=Schön HR, Dorn R, Barthel P, Schömig A |title=Effects of 12 months quinapril therapy in asymptomatic patients with chronic aortic regurgitation |journal=[[The Journal of Heart Valve Disease]] |volume=3 |issue=5 |pages=500–9 |year=1994 |month=September |pmid=8000584 |doi= |url= |accessdate=2011-03-23}}</ref>
 
==AHA guidelines for use of Vasodilator therapy in Chronic Aortic Insufficiency==
{{cquote|'''Class I'''
Vasodilator therapy is indicated for chronic therapy in patients with severe AR who have symptoms or LV dysfunction when surgery is not recommended because of additional cardiac or noncardiac factors.
 
'''Class IIa'''
Vasodilator therapy is reasonable for short-term therapy to improve the hemodynamic profile of patients with severe heart failure symptoms and severe LV dysfunction before proceeding with AVR.
 
'''Class IIb'''
Vasodilator therapy may be considered for long-term therapy in asymptomatic patients with severe AR who have LV dilatation but normal systolic function.
 
'''Class III'''
# Vasodilator therapy is not indicated for long-term therapy in asymptomatic patients with mild to moderate AR and normal LV systolic function.
# Vasodilator therapy is not indicated for long-term therapy in asymptomatic patients with LV systolic dysfunction who are otherwise candidates for AVR.
# Vasodilator therapy is not indicated for long-term therapy in symptomatic patients with either normal LV function or mild to moderate LV systolic dysfunction who are otherwise candidates for AVR.}}


==References==
==References==

Revision as of 04:23, 24 March 2011

WikiDoc Resources for Aortic insufficiency medical management

Articles

Most recent articles on Aortic insufficiency medical management

Most cited articles on Aortic insufficiency medical management

Review articles on Aortic insufficiency medical management

Articles on Aortic insufficiency medical management in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Aortic insufficiency medical management

Images of Aortic insufficiency medical management

Photos of Aortic insufficiency medical management

Podcasts & MP3s on Aortic insufficiency medical management

Videos on Aortic insufficiency medical management

Evidence Based Medicine

Cochrane Collaboration on Aortic insufficiency medical management

Bandolier on Aortic insufficiency medical management

TRIP on Aortic insufficiency medical management

Clinical Trials

Ongoing Trials on Aortic insufficiency medical management at Clinical Trials.gov

Trial results on Aortic insufficiency medical management

Clinical Trials on Aortic insufficiency medical management at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Aortic insufficiency medical management

NICE Guidance on Aortic insufficiency medical management

NHS PRODIGY Guidance

FDA on Aortic insufficiency medical management

CDC on Aortic insufficiency medical management

Books

Books on Aortic insufficiency medical management

News

Aortic insufficiency medical management in the news

Be alerted to news on Aortic insufficiency medical management

News trends on Aortic insufficiency medical management

Commentary

Blogs on Aortic insufficiency medical management

Definitions

Definitions of Aortic insufficiency medical management

Patient Resources / Community

Patient resources on Aortic insufficiency medical management

Discussion groups on Aortic insufficiency medical management

Patient Handouts on Aortic insufficiency medical management

Directions to Hospitals Treating Aortic insufficiency medical management

Risk calculators and risk factors for Aortic insufficiency medical management

Healthcare Provider Resources

Symptoms of Aortic insufficiency medical management

Causes & Risk Factors for Aortic insufficiency medical management

Diagnostic studies for Aortic insufficiency medical management

Treatment of Aortic insufficiency medical management

Continuing Medical Education (CME)

CME Programs on Aortic insufficiency medical management

International

Aortic insufficiency medical management en Espanol

Aortic insufficiency medical management en Francais

Business

Aortic insufficiency medical management in the Marketplace

Patents on Aortic insufficiency medical management

Experimental / Informatics

List of terms related to Aortic insufficiency medical management

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Varun Kumar, M.B.B.S.; Lakshmi Gopalakrishnan, M.B.B.S.

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [3] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Medical therapy of chronic aortic insufficiency involves the use of vasodilators. Small trials have demonstrated a benefit from the administration of ACE inhibitors, nifedipine, sodium nitroprusside and hydralazine in improving left ventricular wall stress, ejection fraction, and left ventricular mass [1] [2] [3] [4]. The use of these vasodilators is indicated only in those individuals who suffer from hypertension in addition to aortic insufficiency. The goal in using these pharmacologic agents is to decrease the afterload so that the left ventricle is unloaded. This results in reduction in left ventricular end diastolic pressure thereby preserving the left ventricular systolic function and also benefits the patients in left ventricular failure secondary to aortic insufficiency.

Long term therapy with nifedipine and hydralazine have shown to increase left ventricular ejection fraction, reduce left ventricular end diastolic volume and reduction in left ventricular mass thereby delaying the need for valve surgery [5] [6] [7]. While ACE inhibitors such as enalapril and quinapril have shown to decrease left ventricular mass and end diastolic volume but with no influence on ejection fraction [8] [9]

AHA guidelines for use of Vasodilator therapy in Chronic Aortic Insufficiency

Class I

Vasodilator therapy is indicated for chronic therapy in patients with severe AR who have symptoms or LV dysfunction when surgery is not recommended because of additional cardiac or noncardiac factors.

Class IIa Vasodilator therapy is reasonable for short-term therapy to improve the hemodynamic profile of patients with severe heart failure symptoms and severe LV dysfunction before proceeding with AVR.

Class IIb Vasodilator therapy may be considered for long-term therapy in asymptomatic patients with severe AR who have LV dilatation but normal systolic function.

Class III

  1. Vasodilator therapy is not indicated for long-term therapy in asymptomatic patients with mild to moderate AR and normal LV systolic function.
  2. Vasodilator therapy is not indicated for long-term therapy in asymptomatic patients with LV systolic dysfunction who are otherwise candidates for AVR.
  3. Vasodilator therapy is not indicated for long-term therapy in symptomatic patients with either normal LV function or mild to moderate LV systolic dysfunction who are otherwise candidates for AVR.

References

  1. Bolen JL, Alderman EL (1976). "Hemodynamic consequences of afterload reduction in patients with chronic aortic regurgitation". Circulation. 53 (5): 879–83. PMID 1260993. Retrieved 2011-03-23. Unknown parameter |month= ignored (help)
  2. Miller RR, Vismara LA, DeMaria AN, Salel AF, Mason DT (1976). "Afterload reduction therapy with nitroprusside in severe aortic regurgitation: improved cardiac performance and reduced regurgitant volume". The American Journal of Cardiology. 38 (5): 564–7. PMID 983953. Unknown parameter |month= ignored (help); |access-date= requires |url= (help)
  3. Greenberg BH, DeMots H, Murphy E, Rahimtoola S (1980). "Beneficial effects of hydralazine on rest and exercise hemodynamics in patients with chronic severe aortic insufficiency". Circulation. 62 (1): 49–55. PMID 7379285. Retrieved 2011-03-23. Unknown parameter |month= ignored (help)
  4. Fioretti P, Benussi B, Scardi S, Klugmann S, Brower RW, Camerini F (1982). "Afterload reduction with nifedipine in aortic insufficiency". The American Journal of Cardiology. 49 (7): 1728–32. PMID 7081058. Unknown parameter |month= ignored (help); |access-date= requires |url= (help)
  5. Scognamiglio R, Rahimtoola SH, Fasoli G, Nistri S, Dalla Volta S (1994). "Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function". The New England Journal of Medicine. 331 (11): 689–94. doi:10.1056/NEJM199409153311101. PMID 8058074. Retrieved 2011-03-23. Unknown parameter |month= ignored (help)
  6. Greenberg B, Massie B, Bristow JD, Cheitlin M, Siemienczuk D, Topic N, Wilson RA, Szlachcic J, Thomas D (1988). "Long-term vasodilator therapy of chronic aortic insufficiency. A randomized double-blinded, placebo-controlled clinical trial". Circulation. 78 (1): 92–103. PMID 3289791. Retrieved 2011-03-23. Unknown parameter |month= ignored (help)
  7. Scognamiglio R, Fasoli G, Ponchia A, Dalla-Volta S (1990). "Long-term nifedipine unloading therapy in asymptomatic patients with chronic severe aortic regurgitation". Journal of the American College of Cardiology. 16 (2): 424–9. PMID 2197314. Retrieved 2011-03-23. Unknown parameter |month= ignored (help)
  8. Lin M, Chiang HT, Lin SL, Chang MS, Chiang BN, Kuo HW, Cheitlin MD (1994). "Vasodilator therapy in chronic asymptomatic aortic regurgitation: enalapril versus hydralazine therapy". Journal of the American College of Cardiology. 24 (4): 1046–53. PMID 7930196. Retrieved 2011-03-23. Unknown parameter |month= ignored (help)
  9. Schön HR, Dorn R, Barthel P, Schömig A (1994). "Effects of 12 months quinapril therapy in asymptomatic patients with chronic aortic regurgitation". The Journal of Heart Valve Disease. 3 (5): 500–9. PMID 8000584. Unknown parameter |month= ignored (help); |access-date= requires |url= (help)

Template:WH Template:WS